EPIPHARE Scientific Interest Group in Epidemiology of Health Products, (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
Faculté de Pharmacie, Université Paris-Saclay, 92296, Châtenay-Malabry, France.
Nat Commun. 2022 Jun 25;13(1):3633. doi: 10.1038/s41467-022-31401-5.
Cases of myocarditis and pericarditis have been reported following the receipt of Covid-19 mRNA vaccines. As vaccination campaigns are still to be extended, we aimed to provide a comprehensive assessment of the association, by vaccine and across sex and age groups. Using nationwide hospital discharge and vaccine data, we analysed all 1612 cases of myocarditis and 1613 cases of pericarditis that occurred in France in the period from May 12, 2021 to October 31, 2021. We perform matched case-control studies and find increased risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose, with adjusted odds ratios of myocarditis of 8.1 (95% confidence interval [CI], 6.7 to 9.9) for the BNT162b2 and 30 (95% CI, 21 to 43) for the mRNA-1273 vaccine. The largest associations are observed for myocarditis following mRNA-1273 vaccination in persons aged 18 to 24 years. Estimates of excess cases attributable to vaccination also reveal a substantial burden of both myocarditis and pericarditis across other age groups and in both males and females.
心肌炎和心包炎病例在接种新冠病毒 mRNA 疫苗后有报道。由于疫苗接种仍在扩大，我们旨在通过疫苗接种和跨性别和年龄组，对这种关联进行全面评估。我们使用全国性的住院和疫苗数据，分析了 2021 年 5 月 12 日至 2021 年 10 月 31 日期间在法国发生的 1612 例心肌炎和 1613 例心包炎病例。我们进行了匹配病例对照研究，发现接种后第一周，尤其是第二剂后，心肌炎和心包炎的风险增加，调整后的 BNT162b2 疫苗接种后心肌炎的比值比为 8.1（95%置信区间[CI]，6.7 至 9.9），mRNA-1273 疫苗的比值比为 30（95%CI，21 至 43）。mRNA-1273 疫苗接种后 18 至 24 岁人群的心肌炎相关性最大。归因于疫苗接种的额外病例估计也揭示了其他年龄组以及男性和女性中两种疾病的大量负担。
